Lexeo Therapeutics, Inc. Common Stock Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2023
2022
2021
2020
-59M
-66M
2M
3M
1M
1M
0M
0M
104M
0M
-0 %
0M
0M
4M
125M
44M
81M
-60M
-55M
-59M
1M
2M
0M
2M
-1M
1M
0M
0M
-0 %
0M
0M
0M
81M
-55M
136M
-55M
-44M
-51M
0M
0M
0M
6M
0M
0M
151M
0M
-0 %
0M
0M
151M
136M
106M
29M
-44M
-3M
-5M
0M
0M
2M
0M
0M
0M
32M
0M
-0 %
0M
0M
32M
29M
29M
0M
-3M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
4Q2023
3Q2023
2Q2023
4Q2022
3Q2022
-14M
-14M
0M
1M
0M
-1M
0M
0M
100M
0M
-0 %
0M
0M
100M
125M
86M
39M
-14M
-14M
-20M
0M
1M
0M
5M
0M
0M
4M
0M
-0 %
0M
0M
4M
39M
-7M
46M
-14M
0M
-13M
0M
0M
0M
0M
0M
0M
0M
0M
-0 %
0M
0M
0M
46M
0M
81M
0M
-17M
-15M
0M
1M
0M
-3M
0M
0M
0M
0M
-0 %
0M
0M
0M
81M
-17M
97M
-17M
-12M
-17M
0M
0M
0M
4M
0M
0M
0M
0M
0 %
0M
0M
0M
97M
-12M
110M
-12M